Clinical Report: Personalized Osilodrostat Therapy for ACTH-Dependent Cushing’s Syndrome
Overview
This study evaluates the real-world effectiveness and safety of osilodrostat in patients with ACTH-dependent Cushing’s syndrome.
Background
Cushing’s syndrome is a serious endocrine disorder characterized by excessive cortisol production, primarily due to ACTH dependence. Effective management is crucial due to the associated complications, including hypertension and diabetes. Osilodrostat, an 11β-hydroxylase inhibitor, has emerged as a treatment option.
Data Highlights
Parameter
Result
Therapeutic effect achieved
92%
Median dose
5 mg/day
Morning cortisol normalization
92%
Urinary free cortisol normalization
75%
Median clinical score reduction
9 to 4
Muscle strength improvement
50% to 75% of normal
Systolic/diastolic BP reduction
142/87 to 124/70 mmHg
Adverse events
Mild to moderate
Key Findings
Osilodrostat was first-line therapy in 12 out of 26 patients.
A titration regimen was utilized in 21 patients, with a block-and-replace approach in five.
92% of patients achieved therapeutic effects within 14 days at a median dose of 5 mg/day.
Significant reductions in blood pressure allowed for antihypertensive therapy reduction in 22 of 23 patients.
Adverse events were primarily mild to moderate, with fatigue and nausea reported in 34.6% of cases.
Clinical Implications
The findings suggest that osilodrostat can provide rapid biochemical control and clinical improvement in patients with ACTH-dependent Cushing’s syndrome. Clinicians should consider its use in cases where surgical options are limited or ineffective.
Conclusion
Osilodrostat demonstrates significant efficacy and a manageable safety profile in real-world settings for patients with ACTH-dependent Cushing’s syndrome.
